Searching for the optimal predictor of ciprofloxacin resistance in Klebsiella pneumoniae by using in vitro dynamic models

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1208-1215

  Strukova, Elena N ^a   Portnoy, Yury A ^a   Romanov, Andrey V ^b   Edelstein, Mikhail V ^b   Zinner, Stephen H ^c   Firsov, Alexander A ^a  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MUTANT; MUTANT PREVENTION CONCENTRATION; PHARMACODYNAMIC PARAMETERS; PRIORITY JOURNAL; BIOLOGICAL MODEL; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MUTATION;

EID: 84960130126     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02334-15     Document Type: Article

References (36)

1. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. 2011. Tackling antibiotic resistance. Nat Rev Microbiol 9:894-896. http://dx.doi.org/10.1038/nrmicro2693.
2. Butler MS, Blaskovich MA, Cooper MA. 2013. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo) 66:571-591. http://dx.doi.org/10.1038/ja.2013.86.
3. Lister P. 2006. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Biochem Pharmacol 71:1057-1065. http://dx.doi.org/10.1016/j.bcp. 2005.10.038.
4. Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA. 2015. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 36:136-153. http://dx.doi.org/10.1055/s-0034-1398490.
5. Firsov AA, Zinner SH, Lubenko IY. 2007. In vitro dynamic models as tools to predict antibiotic pharmacodynamics, p 45-78. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed, section II. Nonclinical models of infection. Informa Healthcare USA, New York, NY.
6. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47:1604-1613. http://dx.doi.org/10.1128/AAC.47.5.1604-1613.2003.
7. Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA, Zinner SH. 2004. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 54:178-186. http://dx.doi.org/10.1093/jac/dkh242.
8. Firsov AA, Smirnova MV, Strukova EN, Vostrov SN, Portnoy YA, Zinner SH. 2008. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Agents 32:488-493. http://dx.doi.org/10.1016/j.ijantimicag.2008.06.031.
9. Firsov AA, Strukova EN, Shlykova DS, Portnoy YA, Kozyreva VK, Edelstein MV, Dovzhenko SA, Kobrin MB, Zinner SH. 2013. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother 57:4956-4962. http://dx.doi.org/10.1128/AAC.00578-13.
10. Firsov AA, Portnoy YA, Strukova EN, Shlykova DS, Zinner SH. 2014. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. Int J Antimicrob Agents 44:301-305. http://dx.doi.org/10.1016/j.ijantimicag.2014.06.013.
11. Firsov AA, Strukova EN, Portnoy YA, Shlykova DS, Zinner SH. 2015. Bacterial antibiotic resistance studies using in vitro dynamic models: population analysis vs. susceptibility testing as endpoints of mutant enrichment. Int J Antimicrob Agents 46:313-318. http://dx.doi.org/10.1016/j.ijantimicag.2015.06.007.
12. MacGowan AP, Rogers CA, Holt HA, Bowker KE. 2003. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 47:1088-1095. http://dx.doi.org/10.1128/AAC.47.3.1088-1095.2003.
13. Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao X, Drlica K, Firsov AA. 2003. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52:616-622. http://dx.doi.org/10.1093/jac/dkg401.
14. Oonishi Y, Mitsuyama O, Yamaguchi K. 2007. Effect of GrlA mutation on the development quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model. J Antimicrob Chemother 60:1030-1037. http://dx.doi.org/10.1093/jac/dkm344.
15. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 51:744-747. http://dx.doi.org/10.1128/AAC.00334-06.
16. Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X. 2011. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacinresistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother 55:2409-2412. http://dx.doi.org/10.1128/AAC.00975-10.
17. Gebru E, Choi M-J, Lee S-J, Damte D, Park SC. 2011. Mutantprevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin. J Med Microbiol 60:1512-1522. http://dx.doi.org/10.1099/jmm.0.028654-0.
18. Croisier D, Etienne M, Piroth L, Bergoin E, Lequeu C, Portier H, Chavanet P. 2004. In vivo pharmacodynamics efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 54:640-647. http://dx.doi.org/10.1093/jac/dkh393.
19. Zhao X, Drlica K. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33:147-156.
20. Blondeau JM, Hansen G, Metzler K, Hedlin P. 2004. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 16(Suppl 3):S1-S19.
21. Olofsson SK, Marcusson LL, Lindgren PK, Hughes D, Cars O. 2006. Selection of ciprofloxacin resistance of Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57:1116-1121. http://dx.doi.org/10.1093/jac/dkl135.
22. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. Eighth edition. CLSI document M-07-08. CLSI, Wayne, PA.
23. Firsov AA, Golikova MV, Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, Zinner SH. 2015. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus. Antimicrob Agents Chemother 59:1014-1019. http://dx.doi.org/10.1128/AAC.04214-14.
24. Wilson APR, Grüneberg RN. 1997. Ciprofloxacin: 10 years of clinical experience. Maxim Medical, Oxford, United Kingdom.
25. Firsov AA, Saverino D, Ruble M, Gilbert D, Manzano B, Medeiros AA, Zinner SH. 1996. Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother 40:734-738.
26. Weigel LM, Steward SD, Tenover FC. 1998. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 42:2661-2667.
27. Zimhony O, Vilchèze C, Arai M, Welch JT, Jacobs WR, Jr. 2006. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrob Agents Chemother 50:3179-3182. http://dx.doi.org/10.1128/AAC.00218-06.
28. Schubert S, Dalhoff A. 2006. Low propensity for development of resistance to MCB3681, the active moiety of oxaquin (MCB3837), in grampositive bacteria with vancomycin-, linezolid-, methicillin- and/or ciprofloxacin resistances, abstr F1-1968. Abstr 46th Intersci Conf Antimicrob Agents Chemother.
29. Hooper DC. 2003. Mechanisms of quinolone resistance, p 41-67. In Hooper DC, Rubinstein E (ed), Quinolone antimicrobial agents, 3rd ed. ASM Press, Washington, DC.
30. Sáenz Y, Zarazaga M, Briñas L, Ruiz-Larrea F, Torres C. 2003. Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals. J Antimicrob Chemother 51:1001-1005. http://dx.doi.org/10.1093/jac/dkg168.
31. Dalhoff A. 2012. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis 2012:976273. http://dx.doi.org/10.1155/2012/976273.
32. Bialek-Davenet S, Marcon E, Leflon-Guibout V, Lavigne JP, Bert F, Moreau R, Nicolas-Chanoine MH. 2011. In vitro selection of ramR and soxR mutants overexpressing efflux systems by fluoroquinolones as well as cefoxitin in Klebsiella pneumoniae. Antimicrob Agents Chemother 55:2795-2802. http://dx.doi.org/10.1128/AAC.00156-11.
33. Martínez-Martínez L, Pascual A, Conejo MDC, García I, Joyanes P, Doménech-Sánchez A, Benedí VJ. 2002. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob Agents Chemother 46:3926-3932. http://dx.doi.org/10.1128/AAC.46.12.3926-3932.2002.
34. Aathithan S, French GL. 2011. Prevalence and role of efflux pump activity in ciprofloxacin resistance in clinical isolates of Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 30:745-752. http://dx.doi.org/10.1007/s10096-010-1147-0.
35. Chen FJ, Lauderdale TL, Ho M, Lo HJ. 2003. The roles of mutations in gyrA, parC, and ompK35 in fluoroquinolone resistance in Klebsiella pneumoniae. Microb Drug Resist 9:265-271. http://dx.doi.org/10.1089/107662903322286472.
36. Skopková-Zarnayová M, Siebor E, Rovná D, Bujdáková H, Neuwirth C. 2005. Outer membrane protein profiles of clonally related Klebsiella pneumoniae isolates that differ in cefoxitin resistance. FEMS Microbiol Lett 243:197-203. http://dx.doi.org/10.1016/j.femsle.2004.12.023.